Gregory T. Lucier was chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion in 2014. During Mr. Lucier’s 11-year tenure, he led the company from a small start-up known as Invitrogen in 2003 and directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. By 2008, he had transformed the organization into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.
Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his 25+ years of strategic management experience to help champion an era of personalized medicine.
Kim Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting- edge therapeutic start-ups, using her expertise to identify companies with promising molecular and companion diagnostics that support personalized medicine.
Her present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until its sale to Novartis in February 2010 and BiPar Sciences until its acquisition by Sanofi-Aventis in April 2009.
Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capita and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.
Dr. Kamdar has authored ten papers and received seven patents. She completed her B.A. at Northwestern University and her Ph.D. in biochemistry and genetics at Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego's CONNECT Foundation and the Hastings Center.
John Sage is the Director of Stakeholder Communications at the Bill & Melinda Gates Foundation. Previously, Mr. Sage founded 6H Consulting LLC, where he provided business planning and marketing strategy services for non-profit and for-profit clients. Prior to 6H, he led Pura Vida Coffee through a decade of rapid growth, establishing the company as an early leader in the fair-trade movement while delivering economic benefits to farmers, families and coffee-growing communities. Sage is also a veteran of Microsoft and web pioneer Starwave. In 2005, he was recognized as an Ashoka Fellow for his leadership in the field of social enterprise.
Sage is a graduate of Stanford University and holds an MBA from Harvard Business School.
Dr. Evgeny Zaytsev is a managing partner at RMI Partners, the management company for RusnanoMedInvest. He was previously a general partner at Helix Ventures, which he co-founded to focus on investment in novel therapeutic opportunities. Prior to Helix, Dr. Zaytsev was a partner of the venture capital pioneer Pitch Johnson at Asset Management Company, one of the oldest venture firms in Silicon Valley. Dr. Zaytsev has been involved in more than 30 investments in biomedical companies and is a board member of a number of companies in Silicon Valley and Russia. As an active business community leader, he founded and served as the first president of the US-Russia Technology Symposium at Stanford University (now Global Technology Symposium) and the annual Silicon Valley Open Doors investment conference.
Dr. Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnology. He received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993 from Altai State Medical University. Dr. Zaytsey also earned an MBA from the Stanford Graduate School of Business in 2002.
Dr. Critchfield is chairman, president and CEO of Sera Prognostics, Inc. and the former president of Myriad Genetic Laboratories, Inc. He led its transformation into one of the world’s leading molecular diagnostics companies. Under his direction, Myriad Genetic Laboratories launched seven novel molecular diagnostic products across a variety of technology platforms, posting 52 percent compounded annual revenue growth from 1998 through 2010. Prior to joining Myriad, Dr. Critchfield was Chief Medical & Science Officer at Quest Diagnostics, Inc., overseeing medical affairs and innovation activities during its transition from Corning Clinical Laboratories.
He has also served on the faculty of three medical schools—University of Minnesota, Wayne State University, and Duke University—and was a practicing clinical pathologist with Intermountain Healthcare.